Targeting the cancer neoantigens p53 and KRAS with TCR mimic antibodies

Antib Ther. 2021 Sep 27;4(4):208-211. doi: 10.1093/abt/tbab021. eCollection 2021 Oct.

Authors

Zhijian Duan¹, Mitchell Ho^{1

2}

Affiliations

¹ Antibody Engineering Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
² Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

No abstract available

Keywords: TCR mimic antibody; bispecific antibody or bsAb; cancer immunotherapy; neoantigen; single chain diabody or scDb.

Publication types

News

Grants and funding

ZIC BC011891/ImNIH/Intramural NIH HHS/United States